key: cord-0264947-8wzqgell authors: Shalamova, Lyudmila; Felgenhauer, Ulrike; Schaubmar, Andreas R.; Büttner, Kathrin; Widera, Marek; Ciesek, Sandra; Weber, Friedemann title: Omicron variant of SARS-CoV-2 exhibits an increased resilience to the antiviral type I interferon response date: 2022-01-20 journal: bioRxiv DOI: 10.1101/2022.01.20.476754 sha: db0249f9816a20b6af60f6b57799141d6430a8ad doc_id: 264947 cord_uid: 8wzqgell The new variant of concern (VOC) of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Omicron (B.1.1.529), is genetically very different from other VOCs. We compared Omicron with the preceding VOC Delta (B.1.617.2) and the wildtype strain (B.1) with respect to their interactions with the antiviral type I interferon (IFN-alpha/beta) response in infected cells. Our data indicate that Omicron has gained an elevated capability to suppress IFN-beta induction upon infection and to better withstand the antiviral state imposed by exogenously added IFN-alpha. Omicron (B.1.1.529) is a new variant of concern (VOC) of the pandemic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causing COVID-19. Since its detection in South Africa in November 2021 (1), Omicron has rapidly spread in all countries where it was introduced, indicating elevated infectivity and a certain resistance to pre-existing immunity (2) . These features are due to an unprecedented number of mutations that are distinguishing Omicron from the original coronavirus that emerged in Wuhan, China, at the end of 2019, as well as from the subsequently appearing VOCs like e.g. Delta (B.1.617.2) (1). Omicron exhibits a high resistance to neutralization by antibodies directed against the previously dominant lineages (3) , an increased binding to the main virus receptor ACE2 (4) , and a switch to the endosomal entry route (5) . Moreover, it replicated more efficiently in cells of the upper respiratory tract (5), most likely contributing to its hyper-transmissibility (2). Type I interferons (IFN-alpha/beta) constitute the first line of the innate immune defense against invading viruses (6) . Upon infection, viral hallmark structures like e.g. doublestranded RNA are recognized by cellular sensors that, in turn, initiate a so-called antiviral signaling chain culminating in the induction of genes for IFN-beta and other cytokines. Secreted IFN then binds to its cognate receptor in an autocrine and paracrine fashion to establish an antiviral state in the cell. SARS-CoV-2, like other highly pathogenic viruses (6) , therefore evolved a series of countermeasures that suppress induction of IFNs or the IFN-stimulated signaling (7) . Despite the more than 15 viral proteins exhibiting IFNantagonistic activity, infection by SARS-CoV-2 still induces a certain level of type I IFNs and other cytokines (8) and exogenously added IFN is inhibitory to viral replication (8) (9) (10) . We investigated the capability of Omicron to interact with the antiviral type I IFN system, in comparison to the parental "wildtype" (wt) SARS-CoV-2 strain (B.1) and the still most prevalent VOC, Delta (B.1.617.2). As a first step, induction of innate immunity was measured in the Calu-3 human lung epithelial cell model using RT-qPCR. As representative marker genes, we chose immediate-early virus response cytokines IFNbeta, IFN-lambda1, and CXCL10 (11) , and as positive control for innate immunity marker gene activation we used the IFN-inducing Rift Valley fever virus mutant Clone 13 (11) . Figure 1A shows that all SARS-CoV-2 strains are inducing the cytokine genes, but as expected their induction levels were much lower than for the control virus Clone 13. Strikingly, however, Omicron tended to exhibit the lowest activation levels regarding the three cytokines, especially IFN-beta. Of note, levels of viral RNAs were comparable for all SARS-CoV-2 strains, excluding the possibility that Omicron simply generated less IFNinducing RNA than the other coronaviruses (Fig. 1B) . The results of the induction experiments suggest that Omicron has an improved ability to suppress the induction of antiviral cytokines. In order to investigate the other end of the IFN response, namely sensitivity to exogenously added IFNs, we pre-treated cells with increasing amounts of IFN-alpha, infected them with the various SARS-CoV-2 strains at a low MOI, and measured virus yields 24 h later. (Table 1) revealed that there was no significant difference in the slopes between wt SARS-CoV-2 and Delta, whereas the slopes of wt SARS-CoV-2 vs. Omicron as well as of Delta vs. Omicron were significantly different. These data indicate that Omicron has gained an increased resistance to human type I IFNs. Exogenously added IFNs were shown to restrict the original wt SARS-CoV-2 in cell culture (8) (9) (10) , and in patients an early type I IFN therapy is associated with reduced mortality (12) . This may also apply to the IFN that is endogenously produced by the infected individual, as the strength of the IFN response correlates with disease severity. In children, a pre-activated IFN system that enables a rapid and strong antiviral response is controlling infection (13) , whereas in the elderly the IFN system is less active and can be additionally hampered by neutralizing anti-IFN autoantibodies (14) . Thus, the ability of a virus to suppress IFN induction and antiviral IFN action are important determinants of COVID-19 risk, and the outcome of infection is dependent on the timing, amount and localization of IFN production. Our results are in line with reports that the earlier VOC Alpha suppresses IFN induction more effectively than preceding wt SARS-CoV-2 isolates (15) and that the more pathogenic SARS-CoV-1 from 2003 is less IFN-sensitive than wt SARS-CoV-2 (9, 10). Thus, IFN escape is an additional feature besides antibody escape, increased ACE2 affinity and endosomal entry that may contribute to the hyper-transmissibility of Omicron. Calu-3 cells were seeded into 24-well plates (7.5×10E4 per well) and infected 24 h later at an MOI of 1. At 24 h post-infection, cells were lysed in RLT buffer and total RNA was extracted using the RNeasy mini kit (Qiagen). RNA was reverse transcribed with the prime Script RT reagent kit (Takara). Differential regulation of cellular genes was assessed using Statistical analyses were done using the program package SAS 9.4. Analysis is based on the log10-transformed data shown in Fig. 2A wt SARS-CoV-2 Rapid epidemic expansion of the SARS-CoV-2 Omicron variant in southern Africa Omicron strain spreads with the doubling time of 3.2-3.6 days in South Africa province of Gauteng that achieved herd immunity to Delta variant Reduced Neutralization of SARS-CoV-2 Omicron Variant by Vaccine Sera and monoclonal antibodies Structural basis of SARS-CoV-2 Omicron immune evasion and receptor engagement The SARS-CoV-2 variant, Omicron, shows rapid replication in human primary nasal epithelial cultures and efficiently uses the endosomal route of entry Ten Strategies of Interferon Evasion by Viruses Type I Interferons in COVID-19 Pathogenesis Experimental and natural evidence of SARS-CoV-2-infection-induced activation of type I interferon responses Inhibition of SARS-CoV-2 by type I and type III interferons Type I Interferon Susceptibility Distinguishes SARS-CoV-2 from SARS-CoV Virus-and Interferon Alpha-Induced Transcriptomes of Cells from the Microbat Myotis daubentonii Retrospective Multicenter Cohort Study Shows Early Interferon Therapy Is Associated with Favorable Clinical Responses in COVID-19 Patients Pre-activated antiviral innate immunity in the upper airways controls early SARS-CoV-2 infection in children Autoantibodies neutralizing type I IFNs are present in ~4% of uninfected individuals over 70 years old and account for ~20% of COVID-19 deaths Evolution of enhanced innate immune evasion by the SARS-CoV-2 B.1.1.7 UK variant Transmission of 2019-nCoV Infection from an Asymptomatic Contact in Germany Antibody-Mediated Neutralization of Authentic SARS-CoV-2 B.1.617 Variants Harboring L452R and T478K/E484Q Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR Highly sensitive and broadly reactive quantitative reverse transcription-PCR assay for high-throughput detection of Rift Valley fever virus We thank Christian Drosten and Stefan Poehlmann for kindly providing wt SARS-CoV-2 and Vero E6-TMPRSS2 cells, respectively. Work in the authors' laboratories was funded